Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • WORLD VIEW

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

We must urgently develop measures to tackle the new coronavirus — but safety always comes first, says Shibo Jiang.
  1. Shibo Jiang

    1. Shibo Jiang is a professor of virology at the School of Basic Medical Sciences, Fudan University, Shanghai, China, and at the New York Blood Center, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Around the world, I am seeing efforts to support ‘quick-fix’ programmes aimed at developing vaccines and therapeutics against COVID-19. Groups in the United States and China are already planning to test vaccines in healthy human volunteers. Make no mistake, it’s essential that we work as hard and fast as possible to develop drugs and vaccines that are widely available across the world. But it is important not to cut corners.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 579, 321 (2020)

doi: https://doi.org/10.1038/d41586-020-00751-9

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links